Severe Early‐Onset Fetal Growth Restriction: The Yield of Antenatal and Postnatal Genetic Testing
Prenatal Diagnosis · 2026
DOI: 10.1002/pd.70182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prenatal Diagnosis, 2026. Verfasst von Matthew H Mossayebi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Fetal Growth Retardation, Genetic Testing. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objectives
We evaluated the diagnostic yield of karyotype (KT) and chromosomal microarray (CMA) with isolated severe FGR diagnosed before 32 weeks' gestation. Exome and genome sequencing (ES/GS) level data were available in a subset of this population.
Method
We performed a retrospective review of singleton pregnancies (delivered 2022–2025) with estimated fetal weight or abdominal circumference < 3rd percentile before 32 weeks' gestation, no sonographic structural anomalies, and diagnostic testing (KT, CMA, ES, or GS) via amniocentesis or cord blood. Cases with abnormal cell‐free DNA were excluded.
Results
Forty cases were included (mean diagnosis 26.8 weeks). Testing was performed via amniocentesis in 42% and cord blood in 58%. All KT (27/40) were normal. CMA (39/40) identified one pathogenic CNV (2.5%) and three (7.5%) variants of uncertain significance (VUS). Four (10%) showed ≥ 1 region of absence of heterozygosity (AOH) > 10Mb; one revealed maternal uniparental disomy of chromosome 6. Sequencing ( N = 10) detected one VUS in COL1A1 . Acute viral infection was not observed in any of the cases.
Conclusions
CMA was diagnostic in 2/39 (5.1%) cases, a pathogenic CNV implicating the SHOX gene, and maternal UPD 6, which were consistent with FGR. There was a remarkable rate (10%) of AOH. Further investigation, including placental studies and genome sequencing, may elucidate whether AOH is a contributing factor for FGR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Matthew H Mossayebi, Sophie J Adams, Megan E Bunnell, Stephanie H Guseh, Louise E Wilkins-Haug
Zitieren
APA
Mossayebi, M. H., Adams, S. J., Bunnell, M. E., Guseh, S. H., & Wilkins-Haug, L. E. (2026). Severe Early‐Onset Fetal Growth Restriction: The Yield of Antenatal and Postnatal Genetic Testing. Prenatal Diagnosis. https://doi.org/10.1002/pd.70182
Vancouver
Mossayebi MH, Adams SJ, Bunnell ME, Guseh SH, Wilkins-Haug LE. Severe Early‐Onset Fetal Growth Restriction: The Yield of Antenatal and Postnatal Genetic Testing. Prenatal Diagnosis. 2026. doi:10.1002/pd.70182
BibTeX
@article{Mossayebi2026,
author = {Mossayebi, Matthew H and Adams, Sophie J and Bunnell, Megan E and Guseh, Stephanie H and Wilkins-Haug, Louise E},
title = {Severe Early‐Onset Fetal Growth Restriction: The Yield of Antenatal and Postnatal Genetic Testing},
journal = {Prenatal Diagnosis},
year = {2026},
doi = {10.1002/pd.70182}
}
EUVIMED